{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-064102","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-10-01T11:01:21+00:00","discovered_at":"2026-10-01T11:05:00.261183+00:00","generated_at":"2026-10-12T14:14:15.271564+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Foghorn, Lilly halt FHD-909 Phase 1 expansion; FHTX cuts 40% of staff, cash runway to 2H 2029","bullets":["Foghorn and Eli Lilly will not advance FHD-909 (LY4050784) into the Phase 1 expansion phase after reviewing dose-escalation data; the selective SMARCA2 degrader program also ends.","Workforce reduced by approximately 40%, with roughly 65 full-time employees expected after the cut; reduction substantially complete in Q4 2026.","Charges of about $2.3 million, all future cash, primarily one-time severance and benefits in Q4 2026; runway extended into the second half of 2029.","Remaining focus: selective EP300 degrader, novel oral immunology and inflammation program, selective CBP degrader, and induced proximity platform.","CEO Adrian Gottschalk said SMARCA2/4 synthetic lethality biology did not translate into required efficacy; no further Lilly collaboration activities anticipated."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-064102","json":"https://secwatch.observer/filing/0001628280-26-064102.json","markdown":"https://secwatch.observer/filing/0001628280-26-064102.md","text":"https://secwatch.observer/filing/0001628280-26-064102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/0001628280-26-064102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/fhtx-20260925.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:14:15.271564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}